



TEHRAN UNIVERSITY
OF
MEDICAL SCIENCES

2022



First day: Wednesday –13th Mehr ,1401
(Morning)
(Hall Amiran1)

Chairmen: Ramezani M, Sharifi L

Time 10:20-10:40	10:00-10:05	The outcomes of younger (< 55 years) versus older patients after radical prostatectomy: A Survival analysis	Adib A
	10:05-10:10	Rare case of Small Cell Metastatic Prostatic Adenocarcinoma, properly staged by 68Ga-PSMA PET/CT scan.	Aghai A
	10:10-10:15	Primary renal pelvis and ureter squamous cell carcinoma (SCC): a rare case report and review of literature	Dastgheib N
	10:15-10:20	Effect of treatment modality on quality of life among patients with urinary bladder cancer	Ohadian Moghadam S
	10:20-10:40	The role of Abiraterone acetate for high-risk non-metastatic prostate cancer.	Jamshidi AP (Abidi Co.)

Chairmen: Hadad M, Ohadian Moghadam S, Tavoosian A

Time 12:00-13:00	12:00-12:05	Expression of Melanoma-associated antigen-A6 and –A11 in prostate cancer	Sharifi L
	12:05-12:10	Incidence trend of prostate cancer in Iran using the national pathology-based cancer registry	Sharifi L
	12:10-12:15	Functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian population	Narooi B
	12:15-12:20	The effect of retroperitonealization of ureteroileal anastomosis on perioperative complications of radical cystectomy with ileal conduit urinary diversion	Rezai M

	12:20-12:40	عملکرد مشابه داروی لوپرولاید استات نسبت به الیگارد	Behnamfar A (Varian Co.)
	12:40-13:00	جایگاه بلومکس در درمان های دارویی ناباروری	Otroj E (Tasnim Co.)
Time 15:00-16:00	15:00-15:20	The change of using abiratrone in MOCSPC	Rajabian F (Actero Co.)
	15:20-15:40	استوما سایتینگ در بیماران رادیکال سیستکتومی	Nikfallah A (Coloplast Co.)
	15:40-16:00	Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer:	Sadeghi A.R (Homafarmed Co.)

Second day: Thursday –14th Mehr,1401 (6th October, 2022) (Morning)
(Hall Amiran1)

Virtual Link:

Chairmen: Dialameh H, Radmanesh F			
Time 09:00-10:20	09:00-09:20	Enzalutamide (Novel hormone therapy updates)in Prostate Cancer	Zeighami Sh (Astellas)
	09:20-09:40	استفاده از پروتزه های هیدروفیلیک آلت و تاثیرات آن بر نتیجه اعمال جراحی	Sedigh (Coloplast Co.)
	09:40-10:00	BPH	Amini E (Pharmed Lotus Co.)
	10:00-10:20	سرطان پروستات و محصول رسلیگو	Farzin AR (Tekaje Co.)

Time 10:20-10:40	10:00-10:05	Continuous post-operative bladder irrigation with sterile distilled water is as effective as intravesical gemcitabine instillation in preventing low-risk non-muscle invasive bladder cancer recurrence; A randomized clinical trial	Sadri M
	10:05-10:10	Is the management of non-muscle invasive bladder cancers compatible with the valid guidelines?	Sadri M
	10:10-10:15	Demographic, clinical, and pathological features that significantly affect the survival of kidney cancer patients after surgery.	Sadri M
	10:15-10:20	Recurrent primary malignant melanoma of the urinary bladder; a case report	Behtash N

Second day: Thursday –14th Mehr,1401 (6th October, 2022) (Afternoon)
(Hall Amiran1)

Virtual Link:

Chairmen: Akhavizadegan H, Nostari F			
Time 15:00-16:20	15:00-15:05	Evidence Based Review of Urinary Tract Cancers	Ghamari Z
	15:05-15:10	Total antioxidant Capacity (TAC) and Genitourinary Cancers	Ghamari Z
	15:10-15:15	Review of Association between Genito-Urinary Tract Cancers and Periodontal Disease	Ghamari Z
	15:15-15:20		
	15:20-15:40	Appropriate use criteria for Ga-PSMA PET CT in Prostate Cancer Current international guidelines statement about Lu-PSMA application in Prostate Cancer	Kaghazchi (Khatam PET Scan)
	15:40-16:00	معرفی داروی ابیراترون و نقش آن در درمان سرطان پروستات	Shadi M (Nano Alvand Co.)
	16:00-16:20	Bladder Cancer . CRPC	Masbogh F (Erica Pharmed Co)